Pfizer Sells Incontinence Drug to Novartis
By Business Review Editor
Pharma Deals Review: Vol 2003 Issue 35 (Table of Contents)
Published: 3 Apr-2003
DOI: 10.3833/pdr.v2003.i35.914 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Novartis entered into an agreement with Pfizer to acquire late-stage incontinence treatment Enablex® (darifenacin) a M3 antagonist in phase 3 for the treatment of overactive bladder...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS